Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis

References

• Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2019;15:113–124.
   PubMed Web of Science ®Google Scholar
• Schneider-Gold C, Hagenacker T, Melzer N, et al. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019;12:1756286419832242.
   Web of Science ®Google Scholar
• Dalakas MC. Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies. Curr Opin Neurol. 2020;33(5):545–552.
   PubMed Web of Science ®Google Scholar
• Evoli A. Myasthenia gravis: new developments in research and treatment. Curr Opin Neurol. 2017;30:464–470.
   PubMed Web of Science ®Google Scholar
• Mantegazza R, and Antoni C. When myasthenia gravis is deemed refractory: clinical signposts and treatments strategies. Ther Adv Neurol Dis. 2018;11:1–11.
   Web of Science ®Google Scholar
• Cortes-Vicente E, Alvarez-Velasco R, Segovia S, et al. Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology. 2020;94:1171–1180.
   PubMed Web of Science ®Google Scholar
• Evoli A, Spagni G, Monte G, et al. Heterogeneity in myasthenia gravis: considerations for disease management. Expert Rev Clin Immunol. 2021;17:761–771.
   PubMedGoogle Scholar
• McConville J, Farrugia ME, Beeson D, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol. 2004;55:580–584.
   PubMed Web of Science ®Google Scholar
• Lauriola L, Ranelletti F, Maggiano N, et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology. 2005;64:536–538.
   PubMed Web of Science ®Google Scholar
• Koneczny I, Stevens JAA, De Rosa A, et al. IgG4 autoantibodies against muscle-specific kinase undergo fab-arm exchange in myasthenia gravis patients. J Autoimmunity. 2017; 77: 104–115.
   PubMed Web of Science ®Google Scholar
• Huijbers MG, Zhang W, Klooster R, et al. MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci U S A. 2013;110:20783.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. IgG4-mediated neurological autoimmunities: understanding pathogenicity of IgG4, ineffectiveness of IVIg and long-lasting benefits of anti-B cell therapies. Neurol Neuroimmunol Neuroinflammation. 2022;9:e1116.
   PubMedGoogle Scholar
• Wolfe GI, Kaminski HJ, Aban IB, et al. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomized trial. Lancet Neurol. 2019;18:259–268.
   PubMed Web of Science ®Google Scholar
• Lee I, Kuo HC, Aban IB, et al. Minimal manifestation status and prednisone withdrawal in the MGTX trial. Neurology. 2020;95:e755–66.103.
   PubMed Web of Science ®Google Scholar
• Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2012;12:CD002277.
   PubMedGoogle Scholar
• Dalakas MC. Update on intravenous immunoglobulin in neurology: modulating neuro-autoimmunity, evolving factors on efficacy and dosing and challenges on stopping chronic IVIg therapy. Neurotherapeutics. 2021November11;18:2397–2418
   PubMed Web of Science ®Google Scholar
• Karelis G, Balasa R, De Bleecker JL, et al. A phase 3 multicenter, prospective, open-label efficacy and safety study of immune globulin (Human) 10% caprylate/chromatography purified in patients with myasthenia gravis exacerbations. Eur Neurol. 2019;81:223–230.
   PubMed Web of Science ®Google Scholar
• Barth D, Nabavi Nouri M, Ng E, et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76:2017–2023.
   PubMed Web of Science ®Google Scholar
• Beecher G, Anderson D, Siddiqi Z, et al. Subcutaneous immunoglobulin in myasthenia gravis exacerbation A prospective, open-label trial. Neurology. 2017;89:1–7.
   PubMedGoogle Scholar
• Dalakas MC. Future perspectives in target-specific immunotherapies of myasthenia gravis. Therap Adv Neurol Disorders. 2015;8(6):316–327
   PubMedGoogle Scholar
• Ruff RL, Lisak RP. Nature and action of antibodies in myasthenia gravis. Neurol Clin. 2018;36:275–291.
   PubMedGoogle Scholar
• Cetin H, Vincent A. Pathogenic mechanisms and clinical correlations in autoimmune myasthenic syndromes. Semin Neurol. 2018;38:344–354.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Alexopoulos H, Spaeth P. Complement in autoimmune neurological disorders and emerging complement-targeted therapeutics. Nature Rev Neurol. 2020;16:601–617.
   PubMed Web of Science ®Google Scholar
• Basta M, Illa I, Dalakas MC. Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barré syndrome, myasthenia gravis and dermatomyositis. J Neuroimmunol. 1996;71:227–229.
   PubMed Web of Science ®Google Scholar
• Howard JF Jr. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci. 2018;1412:113–128.
   PubMed Web of Science ®Google Scholar
• Morgan BP, Chamberlain-Banoub J, Neal JW, et al. The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin Exp Immunol. 2006;146:294–302.
   PubMed Web of Science ®Google Scholar
• Chamberlain-Banoub J, Neal JW, Mizuno M, et al. Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clin Exp Immunol. 2006;146:278–286.
   PubMed Web of Science ®Google Scholar
• Kusner LL, Sengupta M, Kaminski HJ. Acetylcholine receptor antibody-mediated animal models of myasthenia gravis and the role of complement. Ann N Y Acad Sci. 2018;1413:136–142.
   PubMed Web of Science ®Google Scholar
• Souroujon MC, Brenner T, Fuchs S. Development of novel therapies for MG: studies in animal models. Autoimmunity. 2010;43:446–460.
   PubMed Web of Science ®Google Scholar
• Farrugia ME, Vincent A. Autoimmune mediated neuromuscular junction defects. Curr Opin Neurol. 2010;23:489–495.
   PubMed Web of Science ®Google Scholar
• Díaz-Manera J, Martínez-Hernández E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology. 2012;78:189–193.
   PubMed Web of Science ®Google Scholar
• Topakian R, Zimprich F, Iglseder S, et al. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria. J Neurol. 2019;266:699–706.
   PubMed Web of Science ®Google Scholar
• Howard JF, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis (REGAIN): a phase 3, randomised, doubleblind, placebo-controlled, multicentre study. Lancet Neurol. 2017 Oct 20;16:976–986. Published Online.
   PubMed Web of Science ®Google Scholar
• Muppidi S, Utsugisawa K, Benatar M, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019;60:14–24.
   PubMed Web of Science ®Google Scholar
• Nowak RJ, Muppidi S, Beydoun SR, et al. Concomitant Immunosuppressive therapy use in eculizumab-treated adults with generalized myasthenia gravis during the REGAIN open-label extension study. Front Neurol. 2020;11:556104.
   PubMed Web of Science ®Google Scholar
• Jacob S, Murai H, Utsugisawa K, et al. Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study. Ther Adv Neurol Disord. 2020;13:1–7.
   Google Scholar
• Murai H, Suzuki S, Hasebe M, et al. Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of postmarketing surveillance. Ther Adv Neurol Disord. 2021;14:17562864211001995.
   Web of Science ®Google Scholar
• Peffault de Latour R, Brodsky RA, Ortiz S, et al. Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies. Br J Haematol. 2020;191:476–485.
   PubMed Web of Science ®Google Scholar
• Howard JF, Nowak RJ, Wolfe GI, et al. Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol. 2020;77:582. Published online.
   PubMed Web of Science ®Google Scholar
• Sampei Z, Haraya K, Tachibana T, et al. Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody. PLoS One. 2018;13:e0209509.
   PubMed Web of Science ®Google Scholar
• Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Investig. 1994;94:1729–1735.
   PubMed Web of Science ®Google Scholar
• Lunemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology–mode of action and clinical efficacy. Nat Rev Neurol. 2015;11:80–89.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993–2000.
   PubMed Web of Science ®Google Scholar
• Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov. 2019;18:707–729.
   PubMed Web of Science ®Google Scholar
• Ricklin D, Reis ES, Mastellos DC, et al. Complement component C3 - the “Swiss army knife” of innate immunity and host defense. Immunol Rev. 2016;274:33–58.
   PubMed Web of Science ®Google Scholar
• Eskandary F, Jilma B, Mühlbacher J, et al. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial. Am J Transplant. 2018;18:916–926.
   PubMed Web of Science ®Google Scholar
• Langereis JD, van den Broek B, Franssen S, et al. Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients. Blood Adv. 2020 Aug 11;4(15):3615–3620.
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715–725. PubMed: 17703228.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Spaeth PJ. The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Disord. 2021;14:1–7.
   Google Scholar
• Howard JF, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled,phase 3 trial. Lancet Neurol. 2021;20:526–536.
   PubMed Web of Science ®Google Scholar
• FDA News Release. FDA approves new treatment for Myasthenia Gravis. [cited 2021 Dec]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-myasthenia-gravis
   Google Scholar
• Bril V, Benatar M, Benatar M, et al. Efficacy and safety of rozanolixizumab in moderate-to-severe generalised myasthenia gravis: a phase 2 RCT. Neurology. 2020 Nov 20. https://doi.org/10.1212/WNL.0000000000011108. Epub ahead of print.
   Google Scholar
• Peter -H-H, Ochs HD, Cunningham-Rundles C, et al. Targeting FcRn for immunomodulation: benefits, risks, and practical considerations. J Allergy Clin Immunol. 2020;146:479–491.e5.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol. 2008;4(10):557–567.
   PubMedGoogle Scholar
• Stathopoulos P, Dalakas MC. Evolution of anti-B-cell therapeutics in autoimmune neurological diseases. Neurotherapeutics. 2022. https://doi.org/10.1007/s13311-022-01196-w
   Google Scholar
• Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther. 2013 Mar;15(1):1–8.
   Google Scholar
• Tandan R, Hehir MK, Waheed W, et al. Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve. 2017;56(2):185–196.
   PubMed Web of Science ®Google Scholar
• Stieglbauer K, Pihler R, Topakian R. 10-year-outcomes after rituximab for myasthenia gravis: efficacy, safety, costs of in hospital care, and impact on childbearing potential. J Neurol Sci. 2017;375:241–244.
   PubMed Web of Science ®Google Scholar
• Brauner S, Eriksson-Dufva A, Albert Hietala M, et al. Comparison between rituximab treatment for new-onset generalized Myasthenia Gravis and refractory generalized myasthenia gravis. JAMA Neurol. 2020 May 4;77:974.
   PubMed Web of Science ®Google Scholar
• Molimard A, Gitiaux C, Barnerias C, et al. Rituximab therapy in the treatment of Juvenile Myasthenia Gravis: the French experience. Neurology. 2022. Publish Ahead of Print. doi:https://doi.org/10.1212/WNL.0000000000200288.
   Google Scholar
• Hehir MK, Hobson-Webb LD, Benatar M. Benatar M Rituximab as treatment for anti-MuSK myasthenia gravis. Neurology. 2017;89:1–9.
   PubMedGoogle Scholar
• Mariapaola Marino M, Basile U, Spagni G, et al. Long-lasting rituximab-induced reduction of specific—but not total—IgG4 in MuSK-positive Myasthenia Gravis. Front Immunol. 2020;11:613. doi: https://doi.org/10.3389/fimmu.2020.00613.
   Google Scholar
• Nowak RJ, Coffey CS, Goldstein JM, et al. NeuroNEXT NN103 BeatMG study team. Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized Myasthenia Gravis: the BeatMG study. Neurology. 2021 Dec 2. doi:https://doi.org/10.1212/WNL.0000000000013121.
   Google Scholar
• Kanth KM, Solorzano GE, Goldman MD. PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents. Neurol Clin Pract. 2016;6:e17–9.131.
   PubMedGoogle Scholar
• Waters MJ, Field D, Ravindran J. Refractory myasthenia gravis successfully treated with ofatumumab. Muscle Nerve. 2019;1–3. https://doi.org/10.1002/mus.26707
   Google Scholar
• Russell A, Yaraskavitch M, Fok D, et al. Obinutuzumab plus Clorambucil in a patient with severe myasthenia gravis and chronic lymphocytic leukemia J. Neuromuscul Dis. 2017;4. 251–257.
   Google Scholar
• Bonello F, Rocchi S, Baila G, et al. Safety of rapid daratumumab infusion: a retrospective, multicenter, real-life analysis on 134 patients with multiple myeloma. Front Oncol. 2022 Mar 14;12:851864.
   PubMedGoogle Scholar
• Pittock SJ, Berthele A, Fujihara K, et al., Eculizumab in aquaporin-4–positive neuromyelitis optica spectrum disorder. N Engl J Med. 381(7): 614–625. 2019.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Fujihara K, Palace J, et al. Long‐term safety and efficacy of eculizumab in aquaporin‐4 IgG‐positive NMOSD. Ann Neurol. 2021;89(6):1088–1098.
   PubMedGoogle Scholar
• Keller CW, Lopez JA, Wendel E-M, et al. Complement activation is a prominent feature of MOGAD. Ann Neurol. 2021;90(6):976–982.
   PubMedGoogle Scholar
• Dalakas MC. Complement in autoimmune inflammatory myopathies, role of myositis-associated antibodies, COVID19-associations and muscle amyloid deposits. Expert Rev Clin Immunol. 2022 Mar 24;18: 413–423.
   PubMedGoogle Scholar